Cantor Fitzgerald reaffirmed their overweight rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report report published on Tuesday, Benzinga reports. They currently have a $50.00 target price on the stock. Several other analysts have also recently issued reports on CRNX. HC Wainwright reissued a buy rating and set a $42.00 […]
Crinetics Pharmaceuticals, Inc (NASDAQ:CRNX) Sees Significant Increase in Short Interest kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.